South Asians and Coronary Plaque Registry
This observational study, called the South Asians and Coronary Plaque Registry, aims to understand why South Asian individuals may have a higher risk of heart disease. Researchers will use a Coronary CT Angiogram (CCTA), which is a special X-ray test, to look at the arteries that supply blood to your heart and identify plaque characteristics. You can join if you are 18 or older and identify as South Asian, or if you are a non-South Asian adult volunteer for comparison. The study hopes to gather information about plaque features to help with future research into heart disease in this group. The current status of the study is unclear, but it plans to enroll 300 participants.
- Study design
- This is an observational study that plans to enroll 300 participants, including South Asian adults and a comparison group of non-South Asian adults.
- What's involved
- If you participate, you will complete a survey about your health, have blood drawn, and undergo a Coronary CT Angiogram (CCTA).
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, which looks at plaque features, is measured at Day 1.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
South Asians and Coronary Plaque Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anand Rohatgi, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number and type of adverse and protective CTA-derived plaque features Number and type of adverse and protective CTA-derived plaque featuresDay 1
There will be several features derived from CTA that are validated adverse features, including plaque volume, thin cap, low attenuation, and necrotic core. Protective features include fibrous cap thickness.